Global Rare Neurological Disease Treatment Market
Rare Neurological Disease Treatment Global Market: Orphan Pharmaceuticals Gaining Popularity
05 janv. 2024 21h03 HE | Research and Markets
Dublin, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The "Rare Neurological Disease Treatment Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. Rare neurological disease...
Longboard Logo.jpg
Longboard Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference
29 sept. 2022 16h01 HE | Longboard Pharmaceuticals, Inc.
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
TIP_link_300x300.jpg
Embolotherapy Market to Garner $5.75Bn, Globally, by 2028 Growing at 8.1% CAGR | Exclusive Research by The Insight Partners
24 août 2022 05h24 HE | The Insight Partners
New York, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Embolotherapy Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Disease...
22157.jpg
Worldwide Neurorehabilitation Industry to 2030 - Rising Demand of Telerehabilitation Presents Opportunities
17 févr. 2022 05h43 HE | Research and Markets
Dublin, Feb. 17, 2022 (GLOBE NEWSWIRE) -- The "Neurorehabilitation Market by Type, Application, and End-User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to...
22157.jpg
Neurological Biomarkers Market by Application, by Type, by End-use, by Region and Forecasts to 2028
06 déc. 2021 06h58 HE | Research and Markets
Dublin, Dec. 06, 2021 (GLOBE NEWSWIRE) -- The "Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's), By Type (Genomic, Proteomic), By...
Longboard Logo.jpg
Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial
08 sept. 2021 07h00 HE | Longboard Pharmaceuticals, Inc.
Favorable safety, tolerability, pharmacokinetics and pharmacodynamics were observed Central 5-HT2c receptor engagement demonstrated by dose- and exposure-dependent increases of prolactin Company...
22157.jpg
Outlook on the Neurological Diseases Treatment Global Market to 2029 - Key Drivers, Challenges and Opportunities
29 avr. 2021 07h18 HE | Research and Markets
Dublin, April 29, 2021 (GLOBE NEWSWIRE) -- The "Neurological Diseases Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies...
22157.jpg
Insights on the Genetic Testing for Epilepsy, Autism, Alzheimer's and Other Neurologic Conditions Global Market to 2025
15 févr. 2021 05h43 HE | Research and Markets
Dublin, Feb. 15, 2021 (GLOBE NEWSWIRE) -- The "Genetic Testing Markets for Epilepsy, Autism, Alzheimer's and Other Neurologic Conditions" report has been added to ResearchAndMarkets.com's offering. ...
Emergen logo.png
Clinical Biomarkers Market to Reach USD 38.79 Billion By 2027 | Global Analysis, Statistics, Industry Revenue, Demand and Trend Analysis Research Report by Emergen Research
11 févr. 2021 11h39 HE | Emergen Research
Vancouver, British Columbia, Feb. 11, 2021 (GLOBE NEWSWIRE) -- The global clinical biomarkers market is expected to reach a market size of USD 38.79 billion at a steady CAGR of 10.2% in 2027,...
Longboard Pharma Logo.jpg
Longboard Pharmaceuticals Appoints Phillip Schneider and Paul Sekhri to Board of Directors
20 janv. 2021 16h30 HE | Longboard Pharmaceuticals, Inc.
SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological...